Result of AGM

RNS Number : 7231I
Oxford Biomedica PLC
03 June 2014
 



Oxford BioMedica plc Annual General Meeting

 

Oxford, UK - 03 June 2014: Oxford BioMedica ("the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, announced today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.

 

In accordance with Listing Rule 9.6.18 the following resolutions are those which were passed at the meeting concerning special business:

 

·      Resolution 8: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares; and

 

·      Resolution 9: to permit the Company to convene general meetings (other than annual general meetings) on not less than 14 days' notice.

 

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company's website at www.oxfordbiomedica.co.uk.

 

Certified copies of the document setting out the above resolutions passed at the 2014 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: http://www.morningstar.co.uk/uk/NSM.

 

The results of the proxy voting in advance of the meeting are shown below.  On the Record Date (1 June 2014) there were 1,416,149,005 1p ordinary shares in issue, each carrying one vote per share.

 

 

 

Resolution

 

Votes

For

Votes at

Chairman's

Discretion

Votes at

other proxy

Discretion

 

Votes

Against

 

Votes

Withheld

 

Total

votes cast

Result









Ordinary resolutions














1

666,687,905

923,289

8,075,255

38,902

42,532

675,767,883

Passed









2

271,899,678

855,355

8,075,255

30,865,202

364,072,393

675,767,883

Passed









3

302,233,865

862,795

8,075,255

457,303

364,138,665

675,767,883

Passed









4

666,042,751

835,902

8,075,255

717,073

96,902

675,767,883

Passed









5

666,025,533

849,296

8,075,255

691,964

125,835

675,767,883

Passed









6

665,987,201

1,012,357

8,075,255

634,469

58,601

675,767,883

Passed









7

666,254,034

1,040,107

8,075,255

266,422

132,065

675,767,883

Passed









Special resolutions














8

665,722,262

1,021,371

8,075,255

789,363

159,632

675,767,883

Passed









9

661,187,722

1,021,229

8,075,255

612,921

4,870,756

675,767,883

Passed









 

 

-Ends-

 

For further information, please contact:

 

 

 

Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer

 

 

 

Tel: +44 (0)1865 783 000

 

 

 

Media Enquiries:

Mary-Jane Elliott/Emma Thompson/Matthew Neal

Consilium Strategic Communications

Tel: +44 (0)20 3709 5700

 

Notes to editors

 

Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

RAGSSFFFDFLSEDM